Results 101 to 110 of about 5,652,960 (255)

СолдатÑкие жены в XVIII – начале XX в.: опыт реконÑтрукции Ñоциального ÑтатуÑа,

, 2006
Pavel P. Shcherbinin
openalex   +1 more source

Тенденции в Ð¿Ñ€Ð¾Ð¸Ð·Ð²Ð¾Ð´Ð¸Ñ‚ÐµÐ»Ð½Ð¾Ñ Ñ‚Ñ‚Ð° на труда в Ð±ÑŠÐ»Ð³Ð°Ñ€Ñ ÐºÐ°Ñ‚Ð° минна Ð¸Ð½Ð´ÑƒÑ Ñ‚Ñ€Ð¸Ñ [PDF]

, 2020
Ð’Ðμñ Ðμð Ð ̧Ð ⁄ Ðœð ̧Ñ‚Ðμð
openalex  

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

ИСХРÐÐÐТРИ ЈÐÐ’ÐОТО ЗДРÐВЈЕ – СОСТОЈБÐ, ПОЛИТИКИ И ПРЕДИЗВИЦИ [PDF]

, 2017
Студијата  Ð·Ð° глобалното оптоварување Ñо болеÑтите од 2013 година покажа дека факторите на ризик поврзани Ñо иÑхраната Ñе доминантни во Ð½Ð°Ñ ...
СпироÑки, Игор
core   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Зачем программирование грамотному человеку? (Ñ Ñ Ñ Ðµ)

, 2012
Ivan Travkin
openalex   +4 more sources

Ð¡ÑŠÑ‰Ð½Ð¾Ñ Ñ‚ и Ð¿Ñ€Ð°ÐºÑ‚Ð¸Ñ‡ÐµÑ ÐºÐ¸ Ð¸Ð·Ð¼ÐµÑ€ÐµÐ½Ð¸Ñ Ð½Ð° Ð»Ð¸Ð´ÐµÑ€Ñ Ñ‚Ð²Ð¾Ñ‚Ð¾ в Ð¼ÐµÐ¶Ð´ÑƒÐ½Ð°Ñ€Ð¾Ð´Ð½Ð¸Ñ Ð¼ÐµÐ½Ð¸Ð´Ð¶Ð¼ÑŠÐ½Ñ‚ [PDF]

, 2020
СР̧Ð ⁄ ÐμÐ ⁄ Ð ⁄ СР̧Ð ⁄ ÐμÐ ⁄ Ð ⁄ Ð ⁄ Ð
openalex  

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Landscape of BRAF transcript variants in human cancer

Molecular Oncology, EarlyView.
We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda, Danilo Tatoni, Gianluca Mattei, Alberto Magi, Romina D'Aurizio, Laura Poliseno   +5 more
wiley   +1 more source